
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. exhibits a positive financial outlook driven by anticipated stronger revenue growth, stemming from an expected increase in market share within the minimally invasive glaucoma surgery (MIGS) sector and more rapid adoption of its TearCare System. The company's Surgical Glaucoma segment is projected to sustain growth consistent with the overall MIGS market, positioning Sight Sciences for enhanced financial performance. Furthermore, analysts have maintained revenue projections of $75 million for 2025 and $82 million for 2026, while also showing improvement in earnings per share (EPS) estimates, indicating ongoing progress towards profitability.
Bears say
Sight Sciences Inc. faces a challenging financial outlook as it reiterated its 2025 revenue guidance of $72-76 million while anticipating mid-single-digit year-over-year declines in its Surgical Glaucoma segment for Q3 2025. The company confronts significant risks, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, delayed insurance coverage for its TearCare system, and persistent cash burn with no signs of improvement. Additionally, management has lowered its adjusted operating expense guidance for 2025, indicating struggles in managing costs despite efforts to achieve annualized savings through a reduction in workforce.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares